McKesson Corporation (NYSE:MCK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 10, Deutsche ...

If you are wondering whether McKesson still looks attractive after its strong run, or whether much of the potential upside is ...

McKesson trades at $825.38 and has moved in lockstep with the market. Its shares have returned 14.5% over the last six months ...

Discover why McKesson (MCK) is a Buy: strong revenue, margin gains, and robust capital returns suggest 13.5% upside. Click here to read my most recent analysis.

The deal will secure part of Cencora's customer base for lucrative cancer drugs. The Conshohocken company also control a ...

McKesson saw strong 2025 growth from GLP-1 tailwinds, but fading momentum, weak margins, and a 21x forward P/E show ...

McKesson Corporation's latest quarterly report presented a nuanced picture for investors. While the healthcare distribution giant comfortably surpassed earni ...

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With roughly $300 billion in annual US healthcare distribution sales, Cencora supplies ...

Wondering if McKesson is still a buy after such a strong run, or if the easy money has already been made? Let us unpack what the current share price really implies about its long term value. Despite ...

In ordering the additional discovery, U.S. District Judge Nina Gershon pointed out that McKesson—represented by Covington & Burling—had told U.S. Magistrate Judge Steven Tiscione “in the strongest ...